Phase 2 COPD Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 2 years or older at the time of signing the consent form.
• People who have received an allogeneic stem cell transplant (a transplant using stem cells from a donor) and have active chronic graft-versus-host disease (cGVHD) — a condition where the donor cells attack the recipient's body — that requires whole-body immune-suppressing treatment.
• People whose cGVHD has not responded to, or has come back after, at least 2 different systemic (whole-body) treatments, meaning the disease kept spreading, got worse, didn't improve within 3 months, or returned after an initial response.
• People who have a combination of both acute and chronic GVHD symptoms at the same time (sometimes called "overlap syndrome").
• People with a general health/functioning score of 60 or above on standard performance scales used for their age group (confirm with trial site).
• People with kidneys, organs, and bone marrow functioning at adequate levels, as measured by blood tests done within 14 days before joining the trial.
• People with a kidney function measurement (creatinine clearance) of 30 mL/minute or above, calculated using standard medical formulas.
• People who are able to use contraception in line with local guidelines for clinical trial participants.
• People who may be taking corticosteroids (a type of immune-suppressing medication), as long as the dose has been stable for at least 2 weeks before starting the trial — topical (skin) and inhaled corticosteroids are also allowed.
• People who may be taking certain other immune-suppressing medications (CNI or mTOR inhibitors such as sirolimus or everolimus), though these are not required.
• People (or their parent/guardian, for children) who are able to give informed consent and agree to follow the trial requirements.

Who may not be able to join:

• People who have acute GVHD only, with no signs of chronic GVHD.
• People who show any signs that their original cancer has come back, or who have developed a post-transplant condition called lymphoproliferative disease.
• People with a past history of acute or chronic pancreatitis (inflammation of the pancreas).
• People with a past history of myositis (inflammation of the muscles).
• People with a serious illness, an uncontrolled infection, or any other health condition that the trial doctor considers would make participation unsafe.
• People who have AIDS (advanced HIV infection).
• People with active Hepatitis B or Hepatitis C infections, as defined by specific blood test results (confirm with trial site).
• People diagnosed with another cancer (other than the one the transplant was done for) within the 3 years before joining the trial — exceptions may apply for certain fully treated cancers, subject to approval by the trial's medical oversight team.
• People who are pregnant or breastfeeding.
• People who have previously been treated with therapies that target a protein called CSF1-R.
• People currently taking other cGVHD treatments beyond corticosteroids, CNI, or mTOR inhibitors.
• People who have taken certain other treatments recently and have not completed the required washout (clearance) period of 2 weeks or 5 half-lives of the drug, whichever is shorter.
• People who have received another experimental treatment within 28 days before joining this trial.
• People currently participating in another interventional (treatment-testing) study.

Important: Always verify eligibility with the trial site directly before applying.